Catalog No.
PHD19501
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human PLCG2 (Leu930-Thr1152).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
PLC-gamma-2,Phosphoinositide phospholipase C-gamma-2,1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2,PLC-IV,Phospholipase C-gamma-2,PLCG2,Phospholipase C-IV
Purification
Purified by antigen affinity column.
Accession
P16885
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Case Report: de novo in-frame deletion in PLCG2 gene: a case report of B-cell lymphopenia, pulmonary bullae, and cutis laxa., PMID:40170866
Monoallelic expression can govern penetrance of inborn errors of immunity., PMID:39743591
Splice site and de novo variants can cause PLCG2-associated immune dysregulation with cold urticaria., PMID:39667583
A guide to selecting high-performing antibodies for PLC-gamma-2 for use in Western Blot, immunoprecipitation and immunofluorescence., PMID:39429638
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing., PMID:39381601
Genetic regulation of B cell receptor signaling pathway: Insights from expression quantitative trait locus analysis using a mixed model., PMID:39236423
PLCG2 variants in cherubism., PMID:39197752
Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor., PMID:38965708
Splice site and de novo mutations can cause mixed dominant negative/gain of function PLCG2-associated immune dysregulation with cold urticaria (CU-PLAID)., PMID:38562814
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL., PMID:38163317
PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants., PMID:37769878
Human PLCG2 haploinsufficiency results in a novel natural killer cell immunodeficiency., PMID:37714437
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy., PMID:37314786
G-CSF drives autoinflammation in APLAID., PMID:36997670
A rare case of PLCG2-associated antibody deficiency and immune dysregulation associated with a synonymous variant in the PLCG2 gene., PMID:36799558
Variant in the PLCG2 Gene May Cause a Phenotypic Overlap of APLAID/PLAID: Case Series and Literature Review., PMID:35955991
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors., PMID:35196427
A novel likely pathogenic PLCG2 variant in a patient with a recurrent skin blistering disease and B-cell lymphopenia., PMID:34768012
Phospholipase Cγ2 Is Essential for Experimental Models of Epidermolysis Bullosa Acquisita., PMID:34656615
PLCγ2 regulates TREM2 signalling and integrin-mediated adhesion and migration of human iPSC-derived macrophages., PMID:34615897
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab., PMID:34500472
The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration., PMID:34157287
There is no gene for CVID - novel monogenetic causes for primary antibody deficiency., PMID:34153571
Case Report: A Rare Case of Autoinflammatory Phospholipase Cγ2 (PLCγ2)-Associated Antibody Deficiency and Immune Dysregulation Complicated With Gangrenous Pyoderma and Literature Review., PMID:34093563
Connection of BANK1, Tolerance, Regulatory B cells, and Apoptosis: Perspectives of a Reductionist Investigation., PMID:33815360
Neutrophil Phospholipase Cγ2 Drives Autoantibody-Induced Arthritis Through the Generation of the Inflammatory Microenvironment., PMID:33645887
Severe epidermolysis bullosa/Kindler syndrome-like phenotype of an autoinflammatory syndrome in a child., PMID:33625737
Novel genetic variants in genes of the Fc gamma receptor-mediated phagocytosis pathway predict non-small cell lung cancer survival., PMID:32676321
Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations., PMID:32671674
BCALM (AC099524.1) Is a Human B Lymphocyte-Specific Long Noncoding RNA That Modulates B Cell Receptor-Mediated Calcium Signaling., PMID:32571842
Phosphoflow Protocol for Signaling Studies in Human and Murine B Cell Subpopulations., PMID:32253241
Spectrum of Genetic Autoinflammatory Diseases Presenting with Cutaneous Symptoms., PMID:32147748
A new report of autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID) with a homozygous pattern from Iran., PMID:32014489
A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases., PMID:31853824
PLAID syndrome: Characteristic presentation and a novel therapeutic option., PMID:31633221
Expanding the clinical features of autoinflammation and phospholipase Cγ2-associated antibody deficiency and immune dysregulation by description of a novel patient., PMID:31465591
Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa., PMID:30619256
Functional characterization of phospholipase C-γ2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder., PMID:30344948
Simulation of the Dynamics of Primary Immunodeficiencies in B Cells., PMID:30116248
Tespa1 Deficiency Dampens Thymus-Dependent B-Cell Activation and Attenuates Collagen-Induced Arthritis in Mice., PMID:29867947
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era., PMID:29743179
A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment., PMID:29371955
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy., PMID:29259203
A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma., PMID:28892521
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia., PMID:28418267
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein., PMID:27542411
Genes associated with common variable immunodeficiency: one diagnosis to rule them all?, PMID:27250108
A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT Lymphoma., PMID:26966907
Autoimmunity and Immune Dysregulation in Primary Immune Deficiency Disorders., PMID:26233425
PLAID: a Syndrome of Complex Patterns of Disease and Unique Phenotypes., PMID:26206677
For research use only. Not for human or drug use.
